|
1
|
Sakaguchi S, Miyara M, Costantino CM and
Hafler DA: FOXP3+ regulatory T cells in the human immune
system. Nat Rev Immunol. 10:490–500. 2010.
|
|
2
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fontenot JD, Gavin MA and Rudensky AY:
Foxp3 programs the development and function of
CD4+CD25+ regulatory T cells. Nat Immunol.
4:330–336. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ghiringhelli F, Ménard C, Martin F and
Zitvogel L: The role of regulatory T cells in the control of
natural killer cells: relevance during tumor progression. Immunol
Rev. 214:229–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kohrt HE, Pillai AB, Lowsky R and Strober
S: NKT cells, Treg, and their interactions in bone marrow
transplantation. Eur J Immunol. 40:1862–1869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clarke SL, Betts GJ, Plant A, et al:
CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune
responses in patients with colorectal cancer. PLoS One. 1:e1292006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trzonkowski P, Szmit E, Myśliwska J,
Dobyszuk A and Myśliwski A: CD4+CD25+ T regulatory cells inhibit
cytotoxic activity of T CD8+ and NK lymphocytes in the direct
cell-to-cell interaction. Clin Immunol. 112:258–267. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou H, Chen L, You Y, Zou L and Zou P:
Foxp3-transduced polyclonal regulatory T cells suppress NK cell
functions in a TGF-beta dependent manner. Autoimmunity. 43:299–307.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lundqvist A, Yokoyama H, Smith A, Berg M
and Childs R: Bortezomib treatment and regulatory T-cell depletion
enhance the antitumor effects of adoptively infused NK cells.
Blood. 113:6120–6127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salagianni M, Lekka E, Moustaki A, et al:
NK cell adoptive transfer combined with Ontak-mediated regulatory T
cell elimination induces effective adaptive antitumor immune
responses. J Immunol. 186:3327–3335. 2011. View Article : Google Scholar
|
|
11
|
Ramos RN, Oliveira CE, Gasparoto TH, et
al: CD25+ T cell depletion impairs murine squamous cell carcinoma
development via modulation of antitumor immune responses.
Carcinogenesis. 33:902–909. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen YL, Chang MC, Chen CA, Lin HW, Cheng
WF and Chien CL: Depletion of regulatory T lymphocytes reverses the
imbalance between pro- and anti-tumor immunities via enhancing
antigen-specific T cell immune responses. PLoS One. 7:e471902012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ling KL, Pratap SE, Bates GJ, et al:
Increased frequency of regulatory T cells in peripheral blood and
tumour infiltrating lymphocytes in colorectal cancer patients.
Cancer Immun. 7:72007.PubMed/NCBI
|
|
14
|
Salama P, Phillips M, Grieu F, et al:
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic
significance in colorectal cancer. J Clin Oncol. 27:186–192. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brudvik KW, Henjum K, Aandahl EM,
Bjørnbeth BA and Taskén K: Regulatory T-cell-mediated inhibition of
antitumor immune responses is associated with clinical outcome in
patients with liver metastasis from colorectal cancer. Cancer
Immunol Immunother. 61:1045–1053. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Curiel TJ, Coukos G, Zou L, et al:
Specific recruitment of regulatory T cells in ovarian carcinoma
fosters immune privilege and predicts reduced survival. Nat Med.
10:942–949. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miller AM, Lundberg K, Ozenci V, et al:
CD4+CD25high T cells are enriched in the tumor and peripheral blood
of prostate cancer patients. J Immunol. 177:7398–7405. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ormandy LA, Hillemann T, Wedemeyer H,
Manns MP, Greten TF and Korangy F: Increased populations of
regulatory T cells in peripheral blood of patients with
hepatocellular carcinoma. Cancer Res. 65:2457–2464. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Vries IJ, Castelli C, Huygens C, et al:
Frequency of circulating Tregs with demethylated FOXP3 intron 1 in
melanoma patients receiving tumor vaccines and potentially
Treg-depleting agents. Clin Cancer Res. 17:841–848. 2011.PubMed/NCBI
|
|
20
|
Sampson JH, Schmittling RJ, Archer GE, et
al: A pilot study of IL-2Ralpha blockade during lymphopenia
depletes regulatory T-cells and correlates with enhanced immunity
in patients with glioblastoma. PLoS One. 7:e310462012. View Article : Google Scholar
|
|
21
|
Rech AJ, Mick R, Martin S, et al: CD25
blockade depletes and selectively reprograms regulatory T cells in
concert with immunotherapy in cancer patients. Sci Transl Med.
4:134ra1622012.
|
|
22
|
Lanier LL: NK cell receptors. Annu Rev
Immunol. 16:359–393. 1998. View Article : Google Scholar
|
|
23
|
Bauer S, Groh V, Wu J, et al: Activation
of NK cells and T cells by NKG2D, a receptor for stress-inducible
MICA. Science. 285:727–729. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pende D, Cantoni C, Rivera P, et al: Role
of NKG2D in tumor cell lysis mediated by human NK cells:
cooperation with natural cytotoxicity receptors and capability of
recognizing tumors of nonepithelial origin. Eur J Immunol.
31:1076–1086. 2001. View Article : Google Scholar
|
|
25
|
Ljunggren HG: Cancer immunosurveillance:
NKG2D breaks cover. Immunity. 28:492–494. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
López-Soto A, Huergo-Zapico L, Galván JA,
et al: Epithelial-mesenchymal transition induces an antitumor
immune response mediated by NKG2D receptor. J Immunol.
190:4408–4419. 2013.PubMed/NCBI
|
|
27
|
Shen Y, Lu C, Tian W, et al: Possible
association of decreased NKG2D expression levels and suppression of
the activity of natural killer cells in patients with colorectal
cancer. Int J Oncol. 40:1285–1290. 2012.PubMed/NCBI
|
|
28
|
Deng L, Zhang H, Luan Y, et al:
Accumulation of foxp3+ T regulatory cells in draining lymph nodes
correlates with disease progression and immune suppression in
colorectal cancer patients. Clin Cancer Res. 16:4105–4112. 2010.
View Article : Google Scholar
|
|
29
|
Okita R, Yamaguchi Y, Ohara M, et al:
Targeting of CD4+CD25high cells while preserving CD4+CD25low cells
with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy
of cancer. Int J Oncol. 34:563–572. 2009.PubMed/NCBI
|
|
30
|
Xu Q, Lee J, Jankowska-Gan E, et al: Human
CD4+CD25low adaptive T regulatory cells suppress delayed-type
hypersensitivity during transplant tolerance. J Immunol.
178:3983–3995. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guerra N, Tan YX, Joncker NT, et al:
NKG2D-deficient mice are defective in tumor surveillance in models
of spontaneous malignancy. Immunity. 28:571–580. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kanellos I, Zacharakis E, Kanellos D, et
al: Prognostic significance of CEA levels and detection of CEA mRNA
in draining venous blood in patients with colorectal cancer. J Surg
Oncol. 94:3–8. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aggarwal C, Meropol NJ, Punt CJ, et al:
Relationship among circulating tumor cells, CEA and overall
survival in patients with metastatic colorectal cancer. Ann Oncol.
24:420–428. 2013. View Article : Google Scholar : PubMed/NCBI
|
